PMID- 26325448
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20181202
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 15
IP  - 12
DP  - 2015
TI  - Prolyl hydroxylase inhibitors act as agents to enhance the efficiency of cell 
      therapy.
PG  - 1739-55
LID - 10.1517/14712598.2015.1084281 [doi]
AB  - INTRODUCTION: In stem cell-based therapy as a subtype of regenerative medicine, 
      stem cells can be used to replace or repair injured tissue and cells in order to 
      treat disease. Stem cells have the ability to integrate into injured areas and 
      produce new cells via processes of proliferation and differentiation. Several 
      studies have demonstrated that hypoxia increases self-renewal, proliferation and 
      post-homing differentiation of stem cells through the regulation of 
      hypoxia-inducible factor-1 (HIF-1)-mediated gene expression. Thus, 
      pharmacological interventions including prolyl hydroxylase (PHD) inhibitors are 
      considered as promising solutions for stem cell-based therapy. PHD inhibitors 
      stabilize the HIF-1 and activate its pathway through preventing proteasomal 
      degradation of HIF-1. AREAS COVERED: This review focuses on the role of hypoxia, 
      HIF-1 and especially PHD inhibitors on cell therapy. PHD structure and function 
      are discussed as well as their inhibitors. In addition, we have investigated 
      several preclinical studies in which PHD inhibitors improved the efficiency of 
      cell-based therapies. EXPERT OPINION: The data reviewed here suggest that PHD 
      inhibitors are effective operators in improving stem cell therapy. However, 
      because of some limitations, these compounds should be properly examined before 
      clinical application.
FAU - Esfahani, Maryam
AU  - Esfahani M
AD  - a 1 Research center for molecular medicine, Hamadan University of Medical 
      Sciences , Hamadan, the Islamic Republic of Iran najafi2535@gmail.com.
FAU - Karimi, Fatemeh
AU  - Karimi F
AD  - a 1 Research center for molecular medicine, Hamadan University of Medical 
      Sciences , Hamadan, the Islamic Republic of Iran najafi2535@gmail.com.
FAU - Afshar, Saeid
AU  - Afshar S
AD  - a 1 Research center for molecular medicine, Hamadan University of Medical 
      Sciences , Hamadan, the Islamic Republic of Iran najafi2535@gmail.com.
FAU - Niknazar, Somayeh
AU  - Niknazar S
AD  - b 2 Shahid Beheshti University of Medical Science, Hearing Disorders Research 
      Center , Tehran, the Islamic Republic of Iran.
FAU - Sohrabi, Sareh
AU  - Sohrabi S
AD  - a 1 Research center for molecular medicine, Hamadan University of Medical 
      Sciences , Hamadan, the Islamic Republic of Iran najafi2535@gmail.com.
FAU - Najafi, Rezvan
AU  - Najafi R
AD  - a 1 Research center for molecular medicine, Hamadan University of Medical 
      Sciences , Hamadan, the Islamic Republic of Iran najafi2535@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150828
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Prolyl-Hydroxylase Inhibitors)
SB  - IM
MH  - Animals
MH  - Cell Differentiation/drug effects/physiology
MH  - Cell Hypoxia/drug effects/physiology
MH  - Cell- and Tissue-Based Therapy/*methods/trends
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*antagonists & inhibitors/genetics
MH  - Prolyl-Hydroxylase Inhibitors/*administration & dosage
MH  - Stem Cell Transplantation/methods/trends
MH  - Treatment Outcome
OTO - NOTNLM
OT  - hypoxia
OT  - hypoxia-inducible factor-1
OT  - prolyl hydroxylase inhibitors
OT  - stem cell therapy
EDAT- 2015/09/02 06:00
MHDA- 2016/07/29 06:00
CRDT- 2015/09/02 06:00
PHST- 2015/09/02 06:00 [entrez]
PHST- 2015/09/02 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
AID - 10.1517/14712598.2015.1084281 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2015;15(12):1739-55. doi: 10.1517/14712598.2015.1084281. 
      Epub 2015 Aug 28.